Oncogenic ABl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway

Genes and Development

Volumn 12, Issue 10, 1998, Pages 1415-1424

  Dai, Zonghan ^a   Quackenbush, Robert C ^b   Courtney, Kevin D ^a   Grove, Matthew ^a   Cortez, David ^a   Reuther, Gary W ^a   Pendergast, Ann Marie ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Abi; Bcr Abl; Ph1 positive leukemia; Ubiquitin dependent proteolysis; V Src

Indexed keywords

PROTEIN TYROSINE KINASE; UBIQUITIN;

ANIMAL CELL; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANIMALIA;

EID: 0032523919     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.12.10.1415     Document Type: Article

References (58)

1. Aberle, H., A. Bauer, J. Stappert, A. Kispert, and R. Kemler. 1997. β-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16: 3797-3804.
2. Bergold, P.J., J.Y. Wang, W.D. Hardy Jr., V. Littau, E. Johnson, and P. Besmer. 1987. Structure and origins of the HZ2-feline sarcoma virus. Virology 158: 320-329.
3. Biesova, Z., C. Piccoli, and W.T. Wong. 1997. Isolation and characterization of e3B1, an eps8 binding protein that regulates cell growth. Oncogene 14: 233-241.
4. Canman, C.E., T.M. Gilmer, S.B. Coutts, and M.B. Kastan. 1995. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes & Dev. 9: 600-611.
5. Clarkson, B.D., A. Strife, D. Wisniewski, C. Lambek, and N. Carpino. 1997. New understanding of the pathogenesis of CML: A prototype of early neoplasia. Leukemia 11: 1404-1428.
6. Cordon-Cardo, C. 1995. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am. J. Pathol. 147: 545-560.
7. Cortez, D., L. Kadlec, and A.M. Pendergast. 1995. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol. Cell. Biol. 15: 5531-5541.
8. Cortez, D., G. Stoica, J.H. Pierce, and A.M. Pendergast. 1996. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene 13: 2589-2594.
9. Cortez, D., G. Reuther, and A.M. Pendergast. 1997. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 15: 2333-2342.
10. Dai, Z. and A.M. Pendergast. 1995. Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl-transforming activity. Genes & Dev. 9: 2569-2582.
11. Daley, G.Q., R.A. Van Etten, and D. Baltimore. 1990. Induction of chronic myelogenous leukemia in mice by the P210bcr/ abl gene of the Philadelphia chromosome. Science 247: 824-830.
12. Deshaies, R.J. 1995. Make it or break it: The role of ubiquitin-dependent proteolysis in cellular regulation. Trends Cell Biol. 5: 428-434.
13. Feig, L.A. and G.M. Cooper. 1988. Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP. Mol. Cell. Biol. 8: 3235-3243.
14. Feldman, R.M., C.C. Correll, K.K. Kaplan, and R.J. Deshaies. 1997. A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p. Cell 91: 221-230.
15. Gishizky, M.L., D. Cortez, and A.M. Pendergast. 1995. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Proc. Natl. Acad. Sci. 92: 10889-10893.
16. Gotoh, A. and H.E. Broxmeyer. 1997. The function of BCR/ABL and related proto-oncogenes. Curr. Opin. Hematol. 4:3-11.
17. Harlow, E. and D. Lane. 1988. Antibodies, a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
18. Haupt, Y., R. Maya, A. Kazaz, and M. Oreb. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387: 296-298.
19. Heisterkamp, N., G. Jenster, J. ten Hoeve, D. Zovich, P.K. Pattengale, and J. Groffen. 1990. Acute leukaemia in bcr/abl transgenic mice. Nature 344: 251-253.
20. Henchoz, S., Y. Chi, B. Catarin, I. Herskowitz, R.J. Deshaies, and M. Peter. 1997. Phosphorylation- and ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor Far1p in budding yeast. Genes & Dev. 11: 3046-3060.
21. Hochstrasser, M. 1995. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr. Opin. Cell. Biol. 7: 215-223.
22. Kaplan, K.B., A.A. Hyman, and P.K. Sorger. 1997. Regulating the yeast kinetochore by ubiquitin-dependent degradation and Skp1p-mediated phosphorylation. Cell 91: 491-500.
23. Kim, T.K. and T. Maniatis. 1996. Regulation of interferon-γ-activated STAT1 by the ubiquitin-proteasome pathway. Science 273: 1717-1719.
24. King, R.W., R.J. Deshaies, J.M. Peters, and M.W. Kirschner. 1996. How proteolysis drives the cell cycle. Science 274: 1652-1659.
25. Kubbutat, M.H.G., S.N. Jones, and K.H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387: 299-303.
26. Kurzrock, R., M. Shtalrid, P. Romero, W.S. Kloetzer, M. Talpas, J.M. Trujillo, M. Blick, M. Beran, and J.U. Gutterman. 1987. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature 325: 631-635.
27. Laneuville, P. 1995. Abl tyrosine protein kinase. Semin. Immunol. 7: 255-266.
28. Li, S., Y. Li, R.W. Carthew, and Z.C. Lai. 1997. Photoreceptor cell differentiation requires regulated proteolysis of the transcriptional repressor Tramtrack. Cell 90: 469-478.
29. Loda, M., B. Cukor, S.W. Tam, P. Lavin, M. Fiorentino, G.F. Draetta, J.M. Jessup, and M. Pagano. 1997. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med. 3: 231-234.
30. Maniatis, T. 1997. Catalysis by a multiprotein IκB kinase complex. Science 278: 818-819.
31. McLaughlin, J., E. Chianese, and O.N. Witte. 1989. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol. Cell. Biol. 9: 1866-1874.
32. Melo, J.V. 1996. The diversity of Bcr-Abl fusion proteins and their relationship to leukemia phenotype. Blood 88: 2375-2384.
33. Nielsen, K.H., A.G. Papageorge, W.C. Vass, B.M. Willumsen, and D.R. Lowy. 1997. The Ras-specific exchange factors mouse Sos (mSos1) and mSos2 are regulated differently: mSos2 contains ubiquitination signals absent in mSos1. Mol. Cell. Biol. 17: 7132-7138.
34. Pagano, M., S.W. Tam, A.M. Theodoras, P. Beer-Romero, G.D. Sal, V. Chau, P.R. Yew, G.F. Draetta, and M. Rolfe. 1997. Role of the ubiquitin-proteasome pathway in regulation abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685.
35. Pendergast, A.M., L.A. Quilliam, L.D. Cripe, C.H. Bassing, Z. Dai, N. Li, A. Batzer, K.M. Rabun, C.J. Der, J. Schlessinger, and M.L. Gishizky. 1993. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75: 175-185.
36. Piao, X., R. Paulson, P. van der Geer, T. Pawson, and A. Bernstein. 1996. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc. Natl. Acad. Sci. 93: 14665-14669.
37. Puil, L., J. Liu, G. Gish, G. Mbamalu, D. Bowtell, P.G. Pelicci, R. Arlinghaus, and T. Pawson. 1994. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 13: 764-773.
38. Raitano, A.B., J.R. Halpern, T.M. Hambuch, and C.L. Sawyers. 1995. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc. Natl. Acad. Sci. 92: 11746-11750.
39. Rebay, I. and G.M. Rubin. 1995. Yan functions as a general inhibitor of differentiation and is negatively regulated by activation of the Ras1/MAPK pathway. Cell 81: 857-866.
40. Rechsteiner, M. and S.W. Rogers. 1996. PEST sequences and regulation by proteolysis. Trends Biochem. Sci. 21: 267-271.
41. Reuther, J.Y., G.W. Reuther, D. Cortez, A.M. Pendergast, and A.S. Baldwin Jr. 1998. A requirement for NF-κB activation in Bcr-Abl-mediated transformation. Genes & Dev. 12: 968-981.
42. Rosenberg, N. and O.N. Witte. 1988. The viral and cellular forms of the Abelson (abl) oncogene. Adv. Virus Res. 35: 39-81.
43. Salgia, R., B. Brunkhorst, E. Pisick, J.L. Li, S.H. Lo, L.B. Chen, and J.D. Griffin. 1995 . Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene 11: 1149-1155.
44. Salgia, R., J.L. Li, D.S. Ewaniuk, W. Pear, E. Pisick, S.A. Burky, T. Ernst, M. Sattler, L.B. Chen, and J.D. Griffin. 1997. BCR/ ABL induces multiple abnormalities of cytoskeletal function. J. Clin. Invest. 100: 46-57.
45. Sanchez-Garcia, I. and G. Grutz. 1995. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc. Natl. Acad. Sci. 92: 5287-5291.
46. Sawyers, C.L., W. Callahan, and O.N. Witte. 1992. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 70: 901-910.
47. _. 1995. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J. Exp. Med. 181: 307-313.
48. Scheffner, M., B.A. Werness, J.M. Huibregtse, A.J. Levine, and P.M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
49. Shi, Y., K. Alin, and S.P. Goff. 1995. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity. Genes & Dev. 9: 2583-2597.
50. Skorski, T., P. Kanakaraj, M. Nieborowska-Skorska, M.Z. Ratajczak, S.C. Wen, G. Zon, A.M. Gewirtz, B. Perussia, and B. Calabretta. 1995. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86: 726-736.
51. Skorski, T., A. Bellacosa, M. Nieborowska-Skorska, M. Majewski, R. Martinez, J.K. Choi, R. Trotta, P. Wlodarski, D. Perrotti, T.O. Chan, M.A. Wasik, P.N. Tsichlis, and B. Calabretta. 1997. Transformation of hematopoietic cells by BCR/ ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 16: 6151-6161.
52. Skowyra, D., K.L. Craig, M. Tyers, S.J. Elledge, and J.W. Harper. 1997. F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 91: 209-219.
53. Tang, A.H., T.P. Neufeld, E. Kwan, and G.M. Rubin. 1997. PHYL acts to down-regulate TTK88, a transcriptional repressor of neuronal cell fates, by a SINA-dependent mechanism. Cell 90: 459-467.
54. Treier, M., L.M. Staszewski, and D. Bohmann. 1994. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78: 787-798.
55. Varshavsky, A. 1997. The ubiquitin system. Trends Biochem. Sci. 22: 383-387.
56. Verma, R., R.S. Annan, M.J. Huddleston, S.A. Carr, G. Reynard, and R.J. Deshaies. 1997. Phosphorylation of Siclp by G1 Cdk required for its degradation and entry into S phase. Science 278: 455-460.
57. Wada, H., S. Mizutani, J. Nishimura, Y. Usuki, M. Kohsaki, M. Komai, H. Kaneko, S. Sakamoto, D. Delia, A. Kanamaru, and E. Kakishita. 1995. Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein. Cancer Res. 55: 3192-3196.
58. Wang, B., T. Mysliwiec, D. Krainc, R.A. Jensen, G. Sonoda, J.R. Testa, E.A. Golemis, and G.D. Kruh. 1996. Identification of ArgBP1, an Arg protein tyrosine kinase binding protein that is the human homologue of a CNS-specific Xenopus gene. Oncogene 12: 1921-1929.